Sumitomo Chemical
Sumitomo Chemical
ChemicalsKey Fundamentals
SmallcapPesticides & AgrochemicalsChemicalsTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.5%
Weaknesses
1- The company has delivered a poor sales growth of 3.81% over past five years.
Growth Rate
AI Analysis — Bull vs Bear
Sumitomo Chemical India has a market capitalisation of about ₹22,479 crore and trades at a P/E of 38.8x and a P/B of 6.63x. The company is almost debt-free, earned an ROE of 18% last year and pays out 34.5% of profits as dividends. Sales have contracted 3% on both a TTM and a 3-year compounded basis, 5-year sales growth is only 3.81%, and the stock has fallen 17% over the past year with 2% CAGR over 3 and 5 years.
- The balance sheet is almost debt-free, so the business carries little financial risk and has room to fund capex or acquisitions internally.
- Return on equity has stayed consistent: 20% over 10 years, 20% over 5 years, 17% over 3 years and 18% last year. This suggests steady capital efficiency through agrochemical cycles.
- Profit has grown at a 24% CAGR over 10 years, well ahead of 16% sales CAGR over the same period. That points to margin expansion and operating leverage over the long run.
- Profits grew 3% on a TTM basis while sales fell 3%. This shows the company protected margins during weak demand and pricing.
- The company keeps a healthy dividend payout ratio of 34.5%, returning a meaningful share of earnings while still retaining capital for growth.
- Five-year profit CAGR of 10% is well above 5-year sales CAGR of about 4%. This indicates better product mix or cost efficiency over the medium term.
- The stock is down 17% over one year, which has pulled the valuation below levels seen when growth was stronger. The P/E is now 38.8x.
- Five-year sales growth is only 3.81%, a sharp slowdown from the 16% 10-year sales CAGR.
- Sales are shrinking: compounded sales growth is -3% on both a TTM and a 3-year basis, which points to extended demand or pricing pressure in agrochemicals.
- A P/E of 38.8x looks high next to 3-year profit CAGR of just 3%, leaving little margin for error if earnings disappoint.
- A P/B of 6.63x against last-year ROE of 18% implies the market is pricing in a recovery in growth that recent numbers have not yet shown.
- Shareholder returns have been weak: the stock fell 17% over one year and delivered only 2% CAGR over both 3 and 5 years, lagging broader Indian equity indices.
- Profit growth has slowed sharply, from 24% CAGR over 10 years to 10% over 5 years and 3% over 3 years. This suggests margin tailwinds may be fading.
- ROE has dipped from a 5-year average of 20% to 17% over 3 years, which hints at mild pressure on returns.
- The dividend yield is only 0.29% despite the 34.5% payout ratio, so income support is limited at the current valuation.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Investor meet scheduled Sep 3 Aug 25
Sumitomo Chemical India will host institutional investors and analysts on September 3, 2026 in Mumbai, organized by Elara Capital. Meetings will cover publicly available information only.
TL;DR: Limited recent news flow for Sumitomo Chemical India with only a routine investor meeting scheduled for Sep 3. No material headwinds or positive catalysts reported in this period. The upcoming analyst meet could provide forward guidance and may drive sentiment depending on management commentary.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 724 | 903 | 540 | 664 | 832 | 971 | 622 | 665 | 1,048 | 914 | 552 | 671 | 1,054 |
| Expenses | 643 | 715 | 474 | 526 | 670 | 729 | 521 | 548 | 828 | 697 | 456 | 539 | 819 |
| Operating Profit | 81 | 188 | 66 | 139 | 162 | 242 | 101 | 117 | 220 | 217 | 96 | 133 | 235 |
| OPM % | 11% | 21% | 12% | 21% | 19% | 25% | 16% | 18% | 21% | 24% | 17% | 20% | 22% |
| Other Income | 18 | 25 | 27 | 27 | 26 | 31 | 31 | 31 | 39 | 39 | 22 | 32 | 74 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Depreciation | 14 | 16 | 16 | 16 | 14 | 15 | 18 | 16 | 15 | 16 | 16 | 16 | 16 |
| PBT | 83 | 196 | 76 | 149 | 173 | 257 | 113 | 132 | 242 | 238 | 100 | 147 | 291 |
| Tax % | 26% | 27% | 27% | 26% | 26% | 26% | 25% | 25% | 26% | 25% | 25% | 25% | 26% |
| Net Profit | 62 | 144 | 55 | 109 | 128 | 191 | 84 | 98 | 180 | 178 | 75 | 111 | 217 |
| EPS in Rs | 1.24 | 2.88 | 1.1 | 2.19 | 2.57 | 3.82 | 1.69 | 1.97 | 3.6 | 3.56 | 1.5 | 2.22 | 4.34 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | 3,186 | 3,192 |
| Expenses | 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,467 | 2,520 | 2,511 |
| Operating Profit | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 | 666 | 680 |
| OPM % | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 21% | 21% |
| Other Income | 8 | 26 | 10 | 31 | 0 | -20 | 19 | 36 | 45 | 96 | 119 | 131 | 166 |
| Interest | 1 | 1 | 1 | 5 | 5 | 7 | 7 | 8 | 6 | 5 | 6 | 7 | 7 |
| Depreciation | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 | 63 | 64 |
| PBT | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 | 727 | 776 |
| Tax % | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% | 25% | — |
| Net Profit | 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | 543 | 580 |
| EPS in Rs | — | — | — | — | — | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | 10.88 | 11.62 |
| Div. Payout % | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% | 12% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | -2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 | 2,885 |
| Borrowings | 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 | 53 |
| Other Liabilities | 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 | 997 |
| Total Liabilities | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 |
| Fixed Assets | 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 482 | 499 |
| CWIP | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 | 20 |
| Investments | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 | 1,226 |
| Other Assets | 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 | 2,690 |
| Total Assets | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 4 | 52 | -21 | 49 | 75 | 222 | 424 | 223 | 389 | 756 | 458 | 443 |
| Investing | -8 | -5 | -289 | -40 | -35 | -118 | -282 | -281 | -327 | -426 | -405 | -329 |
| Financing | 0 | 0 | 276 | 7 | -65 | -61 | -47 | -63 | -73 | -331 | -65 | -81 |
| Net Cash Flow | -4 | 47 | -34 | 16 | -26 | 43 | 95 | -120 | -10 | -1 | -11 | 33 |
| Free Cash Flow | -6 | 44 | -310 | 6 | 36 | 184 | 382 | 111 | 270 | 695 | 431 | 404 |
| CFO/OP | 44 | 102 | 14 | 60 | 56 | 90 | 109 | 61 | 83 | 187 | 100 | 91 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 | 81 |
| Inventory Days | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 154 | 166 |
| Days Payable | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 107 | 86 |
| Cash Conversion Cycle | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 136 | 161 |
| Working Capital Days | 69 | 79 | 113 | 113 | 116 | 109 | 95 | 127 | 136 | 173 | 183 | 155 |
| ROCE % | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% | 23% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sumitomo Chemical insights
60 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Sumitomo Chemical
What does Sumitomo Chemical India Ltd do?
Where is Sumitomo Chemical India Ltd (SUMICHEM) listed?
Which sector does Sumitomo Chemical India Ltd belong to?
What is the market capitalisation of Sumitomo Chemical India Ltd?
What is the PE ratio of Sumitomo Chemical India Ltd?
What is the 52-week high and low of Sumitomo Chemical India Ltd?
Does Sumitomo Chemical India Ltd pay dividends?
What is the Return on Equity (ROE) of Sumitomo Chemical India Ltd?
Company Information
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.[1] [2]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUMICHEM.md for Sumitomo Chemical India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.